DK3631017T3 - Fremgangsmåder til melanompåvisning - Google Patents
Fremgangsmåder til melanompåvisning Download PDFInfo
- Publication number
- DK3631017T3 DK3631017T3 DK18731615.3T DK18731615T DK3631017T3 DK 3631017 T3 DK3631017 T3 DK 3631017T3 DK 18731615 T DK18731615 T DK 18731615T DK 3631017 T3 DK3631017 T3 DK 3631017T3
- Authority
- DK
- Denmark
- Prior art keywords
- melanom
- detection
- methods
- melanom detection
- Prior art date
Links
- 238000001514 detection method Methods 0.000 title 1
- 201000001441 melanoma Diseases 0.000 title 1
- 238000000034 method Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
- C12Q2563/107—Nucleic acid detection characterized by the use of physical, structural and functional properties fluorescence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7023—(Hyper)proliferation
- G01N2800/7028—Cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Mycology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762511058P | 2017-05-25 | 2017-05-25 | |
| PCT/US2018/033658 WO2018217627A1 (en) | 2017-05-25 | 2018-05-21 | Methods for melanoma detection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3631017T3 true DK3631017T3 (da) | 2022-06-20 |
Family
ID=62620988
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18731615.3T DK3631017T3 (da) | 2017-05-25 | 2018-05-21 | Fremgangsmåder til melanompåvisning |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20180340934A1 (enExample) |
| EP (1) | EP3631017B1 (enExample) |
| JP (1) | JP7227964B2 (enExample) |
| KR (1) | KR102763004B1 (enExample) |
| CN (1) | CN111315897B (enExample) |
| AU (1) | AU2018273844B2 (enExample) |
| BR (1) | BR112019024481A2 (enExample) |
| CA (1) | CA3064732A1 (enExample) |
| DK (1) | DK3631017T3 (enExample) |
| ES (1) | ES2920288T3 (enExample) |
| IL (1) | IL270787B2 (enExample) |
| MX (1) | MX2019014026A (enExample) |
| PL (1) | PL3631017T3 (enExample) |
| WO (1) | WO2018217627A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019024481A2 (pt) | 2017-05-25 | 2020-07-14 | Liquid Biopsy Research LLC | métodos para detecção de melanoma |
| US20210108259A1 (en) | 2019-10-10 | 2021-04-15 | Liquid Biopsy Research LLC | Compositions, methods and kits for biological sample and rna stabilization |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2614946A1 (en) * | 2005-01-07 | 2006-07-13 | The Johns Hopkins University | Biomarkers for melanoma |
| US7615349B2 (en) * | 2006-09-07 | 2009-11-10 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Melanoma gene signature |
| EP2080140B1 (en) * | 2006-11-03 | 2013-04-24 | Baylor Research Institute | Diagnosis of metastatic melanoma and monitoring indicators of immunosuppression through blood leukocyte microarray analysis |
| EP2092075A2 (en) * | 2006-11-06 | 2009-08-26 | Source Precision Medicine, Inc. | Gene expression profiling for identification, monitoring and treatment of melanoma |
| US20110070582A1 (en) * | 2008-11-03 | 2011-03-24 | Source Precision Medicine, Inc. d/b/d Source MDX | Gene Expression Profiling for Predicting the Response to Immunotherapy and/or the Survivability of Melanoma Subjects |
| US20110091384A1 (en) * | 2009-10-13 | 2011-04-21 | The Johns Hopkins University | Biomarker for identification of melanoma tumor cells |
| US20140045915A1 (en) * | 2010-08-31 | 2014-02-13 | The General Hospital Corporation | Cancer-related biological materials in microvesicles |
| CN104470920A (zh) * | 2012-07-03 | 2015-03-25 | 通益制药有限公司 | 固态形式的维罗菲尼胆碱盐 |
| AU2015317893B2 (en) * | 2014-09-15 | 2021-05-20 | Clifton Life Sciences LLC | Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm |
| BR112019024481A2 (pt) | 2017-05-25 | 2020-07-14 | Liquid Biopsy Research LLC | métodos para detecção de melanoma |
-
2018
- 2018-05-21 BR BR112019024481-6A patent/BR112019024481A2/pt unknown
- 2018-05-21 CN CN201880049298.1A patent/CN111315897B/zh active Active
- 2018-05-21 JP JP2020516379A patent/JP7227964B2/ja active Active
- 2018-05-21 MX MX2019014026A patent/MX2019014026A/es unknown
- 2018-05-21 EP EP18731615.3A patent/EP3631017B1/en active Active
- 2018-05-21 KR KR1020197038285A patent/KR102763004B1/ko active Active
- 2018-05-21 CA CA3064732A patent/CA3064732A1/en active Pending
- 2018-05-21 ES ES18731615T patent/ES2920288T3/es active Active
- 2018-05-21 WO PCT/US2018/033658 patent/WO2018217627A1/en not_active Ceased
- 2018-05-21 US US15/984,935 patent/US20180340934A1/en not_active Abandoned
- 2018-05-21 PL PL18731615.3T patent/PL3631017T3/pl unknown
- 2018-05-21 AU AU2018273844A patent/AU2018273844B2/en active Active
- 2018-05-21 DK DK18731615.3T patent/DK3631017T3/da active
-
2019
- 2019-11-20 IL IL270787A patent/IL270787B2/en unknown
-
2021
- 2021-09-30 US US17/490,433 patent/US12399179B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7227964B2 (ja) | 2023-02-22 |
| EP3631017A1 (en) | 2020-04-08 |
| MX2019014026A (es) | 2020-08-03 |
| PL3631017T3 (pl) | 2022-09-26 |
| WO2018217627A1 (en) | 2018-11-29 |
| IL270787B2 (en) | 2023-08-01 |
| AU2018273844A1 (en) | 2019-12-19 |
| JP2020524524A (ja) | 2020-08-20 |
| US20180340934A1 (en) | 2018-11-29 |
| BR112019024481A2 (pt) | 2020-07-14 |
| ES2920288T3 (es) | 2022-08-02 |
| IL270787B1 (en) | 2023-04-01 |
| KR102763004B1 (ko) | 2025-02-04 |
| EP3631017B1 (en) | 2022-03-23 |
| CN111315897B (zh) | 2024-10-22 |
| KR20200030034A (ko) | 2020-03-19 |
| US12399179B2 (en) | 2025-08-26 |
| IL270787A (en) | 2020-01-30 |
| CN111315897A (zh) | 2020-06-19 |
| AU2018273844B2 (en) | 2024-11-14 |
| US20230022236A1 (en) | 2023-01-26 |
| CA3064732A1 (en) | 2018-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3711826A4 (en) | RECOGNITION SYSTEM | |
| PL3739299T3 (pl) | Wykrywanie obiektów | |
| EP3541932A4 (en) | INHIBITORS OF CRISPR-CAS9 | |
| EP3408402A4 (en) | MAGNETIC ELECTROCHEMICAL DETECTION | |
| DK3538864T3 (da) | Mikrotom | |
| DK3346961T3 (da) | Anordning til stomi | |
| DK3072835T3 (da) | Fremgangsmåde til fremføring | |
| DK3298718T3 (da) | Teknikker til signal-forlængelsessignalering | |
| EP3313828A4 (en) | METALLO-BETA-Lactamase INHIBITORS | |
| DE112016000423T8 (de) | Abschnittslinienerkennungsvorrichtung | |
| DK3125898T3 (da) | Farmakofor til trail-induktion | |
| EP3407317C0 (en) | Tamper detection | |
| DK3314010T3 (da) | Fremgangsmåde til detektering af kromosomaberrationer | |
| DK3477274T3 (da) | Lækagedetektering | |
| MA43367A (fr) | Inhibiteurs de métallo-bêta-lactamases | |
| EP2998732C0 (en) | ANALYSIS PROCESS | |
| FI20146115A7 (fi) | Menetelmä kemikaalitestausta varten | |
| DE112017004618T8 (de) | Objekterfassungsvorrichtung | |
| DK3511705T3 (da) | Detekteringsanordning | |
| MA46280A (fr) | Inhibiteurs de la dopamine-b-hydroxylase | |
| DK3606936T3 (da) | Fremgangsmåde til indvinding | |
| DK3589742T3 (da) | Fremgangsmåde til detektering | |
| IT201600092505A1 (it) | Dispositivo di rilevazione di posizione | |
| EP3591899A4 (en) | PATH DETECTION | |
| EP3598129A4 (en) | SAMPLE DETECTION SYSTEM |